Harel Insurance Investments & Financial Services Ltd. Has $5.26 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Harel Insurance Investments & Financial Services Ltd. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,742 shares of the company’s stock after buying an additional 349 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned about 0.06% of Medpace worth $5,255,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Atria Investments Inc raised its holdings in shares of Medpace by 7.7% in the 2nd quarter. Atria Investments Inc now owns 3,079 shares of the company’s stock worth $966,000 after acquiring an additional 221 shares during the last quarter. HBK Sorce Advisory LLC increased its holdings in Medpace by 3.3% during the 2nd quarter. HBK Sorce Advisory LLC now owns 5,581 shares of the company’s stock worth $1,752,000 after purchasing an additional 176 shares in the last quarter. Hantz Financial Services Inc. raised its stake in shares of Medpace by 5,075.0% in the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after purchasing an additional 203 shares during the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of Medpace in the second quarter worth approximately $327,000. Finally, GWN Securities Inc. bought a new position in shares of Medpace in the second quarter valued at approximately $243,000. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of Medpace stock opened at $584.91 on Friday. The firm has a market cap of $16.48 billion, a PE ratio of 40.90, a P/E/G ratio of 2.67 and a beta of 1.40. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00. The stock has a fifty day moving average price of $515.52 and a 200-day moving average price of $402.72.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same period in the previous year, the firm earned $3.01 EPS. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of Medpace stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total value of $772,896.48. Following the sale, the director owned 10,197 shares of the company’s stock, valued at approximately $4,742,012.88. The trade was a 14.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Jesse J. Geiger sold 19,460 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $605.12, for a total value of $11,775,635.20. Following the completion of the transaction, the president owned 36,503 shares in the company, valued at approximately $22,088,695.36. The trade was a 34.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 88,736 shares of company stock valued at $47,286,494. Corporate insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and upped their price target for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Finally, Cowen restated a “sell” rating on shares of Medpace in a report on Friday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average target price of $475.90.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.